Sino Biological launches 4RISE™ high-throughput wet-lab services to accelerate AI-driven drug discovery

AI-driven protein design is accelerating the discovery of novel protein binders, but experimental validation remains essential to determine whether computational designs translate into meaningful target interactions. To bridge this gap, Sino Biological, Inc., a global leader in recombinant technology, announced its 4RISE™ high-throughput wet-lab validation services for AI-designed protein binders.

Image Credit: Sino Biological Inc.

The services feature 3-hour cell-free expression, AI-ready binding data in as little as 3 days, and real-time API access to structured target-binding data, helping AI-focused life sciences researchers move faster and gain deeper insights. Designed for iterative AI-driven discovery, 4RISE™ combines rapid experimental turnaround, scalable screening workflows, and structured data delivery to support continuous design-test-learn cycles.

"3 hours" and "3 days"

Sino Biological’s XPressMAX™ Cell-Free Protein Synthesis (CFPS) platform enables recombinant protein synthesis in just 3 hours, with expression success rates exceeding 99% in established workflows. Supporting the synthesis of miniproteins, VHHs, scFvs, Fabs, enzymes, and cytokines, the platform accelerates experimental testing of AI-designed protein candidates, enabling faster feedback and design iterations.

Using Carterra high-throughput SPR, Biacore SPR, and Octet BLI, 4RISE™ delivers high-throughput binding screening, kinetic analysis, and affinity determination for candidate protein. Combined with CFPS, the workflow delivers sequence-to-AI-ready binding data in as little as 3 days. Structured binding data are accessible in real time via API, enabling seamless data retrieval for downstream research and analysis.

4 rapid screening services of AI-designed binders

To support diverse research needs in AI-driven binder discovery, 4RISE™ offers flexible screening and characterization workflows tailored to different candidate formats and validation objectives. Rapid Hit Discovery identifies binding-positive miniproteins and VHHs through crude-supernatant screening. Comparative Binder Screening evaluates purified candidates under standardized conditions to support candidate prioritization. Affinity & Kinetic Characterization provides quantitative binding insights for lead selection, while Specialized Binder Expression & Validation supports diverse binder formats through tailored mammalian expression and binding analysis.

Beyond binding, 4RISE™ also provides 20+ developability assays, 1,000+ protein bioactivity assays, and 10+ cell-based functional assays, supporting in-depth candidate evaluation and design optimization.

Proven experience

Sino Biological works with AI companies on wet-lab validation for AI-designed antibody discovery, de novo binder design, and computational protein engineering. 4RISE™ wet-lab validation has supported studies published in Science, Nature Communications, Scientific Reports, and other high-impact journals.

AI-designed molecules need reliable wet-lab experimental evidence to demonstrate their potential. Our integrated capabilities provide the high-quality data researchers need to evaluate candidates quickly, shorten design cycles, and turn promising discoveries into real-world applications.”

Dr. Rob Burgess, Chief Business Officer, Sino Biological US

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sino Biological Inc.. (2026, November 17). Sino Biological launches 4RISE™ high-throughput wet-lab services to accelerate AI-driven drug discovery. News-Medical. Retrieved on November 17, 2026 from https://www.news-medical.net/news/20261117/Sino-Biological-launches-4RISEe284a2-high-throughput-wet-lab-services-to-accelerate-AI-driven-drug-discovery.aspx.

  • MLA

    Sino Biological Inc.. "Sino Biological launches 4RISE™ high-throughput wet-lab services to accelerate AI-driven drug discovery". News-Medical. 17 November 2026. <https://www.news-medical.net/news/20261117/Sino-Biological-launches-4RISEe284a2-high-throughput-wet-lab-services-to-accelerate-AI-driven-drug-discovery.aspx>.

  • Chicago

    Sino Biological Inc.. "Sino Biological launches 4RISE™ high-throughput wet-lab services to accelerate AI-driven drug discovery". News-Medical. https://www.news-medical.net/news/20261117/Sino-Biological-launches-4RISEe284a2-high-throughput-wet-lab-services-to-accelerate-AI-driven-drug-discovery.aspx. (accessed November 17, 2026).

  • Harvard

    Sino Biological Inc.. 2026. Sino Biological launches 4RISE™ high-throughput wet-lab services to accelerate AI-driven drug discovery. News-Medical, viewed 17 November 2026, https://www.news-medical.net/news/20261117/Sino-Biological-launches-4RISEe284a2-high-throughput-wet-lab-services-to-accelerate-AI-driven-drug-discovery.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The 0.05 EU/mg breakthrough: How Sino Biological ProPure™ is redefining the Ultra-Low Endotoxin standard